Pharmaceutical compositions comprising meloxicam
View Patent ↗Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
1. A dosage form comprising a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and a bicarbonate, wherein the dosage form is an oral dosage form having a shorter T max of meloxicam than a reference dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate.
2. The dosage form of claim 1 , containing about 10 mg to about 20 mg of meloxicam.
3. The dosage form of claim 1 , containing about 15 mg of meloxicam.
4. The dosage form of claim 1 , wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.
5. The dosage form of claim 1 , containing about 50 mg to about 200 mg of the SBEβCD.
6. The dosage form of claim 1 , containing about 100 mg of the SBEβCD.
7. The dosage form of claim 1 , wherein the bicarbonate comprises sodium bicarbonate.
8. The dosage form of claim 1 , containing about 400 mg to about 600 mg of the bicarbonate.
9. The dosage form of claim 1 , containing about 500 mg of sodium bicarbonate.
10. The dosage form of claim 1 , further comprising an acid inhibitor.
11. The dosage form of claim 10 , wherein the acid inhibitor is a proton pump inhibitor.
12. The dosage form of claim 11 , wherein the proton pump inhibitor is esomeprazole.
13. The dosage form of claim 9 , wherein about 30 mg to about 50 mg of esomeprazole is present in the dosage form.
14. The dosage form of claim 1 , containing about 40 mg of esomeprazole.
15. The dosage form of claim 11 , wherein the proton pump inhibitor is esomeprazole, omeprazole, lansoprazole, pantoprazole, or rabeprazole.
16. The dosage form of claim 1 , wherein the oral dosage form has been shown to have a T max of meloxicam that is less than about 3 hours in an average person.
17. The dosage form of claim 1 , wherein the oral dosage form has been shown to have a T max of meloxicam that is less than about 2 hours in an average person.
18. The dosage form of claim 1 , wherein the oral dosage form has been shown to have a T max of meloxicam that is less than about 1 hour in an average person.